Abstract:BACKGROUND:Endothelial injury, which may present clinically as hypertension, proteinuria and increased von Willebrand Factor (vWF) level, is a common manifestation in IgA nephropathy (IgAN). However, causal factors for endothelial injury in IgAN are not completely understood. An imbalance of vascular endothelial growth factor/Soluble fms-like tyrosine kinase-1 (VEGF/sFlt-1) has been observed in many diseases with endothelial dysfunction, including pre-eclampsia and diabetic retinopathy, but whether it contributes to endothelial injury in IgAN requires further exploration. METHODS:Initially, 96 IgAN patients and 22 healthy volunteers were enrolled as a discovery cohort. VEGF/sFlt-1, sFlt-1 and VEGF levels were compared between patients with IgAN and healthy volunteers to explore the underlying factors that contribute to endothelial injury in IgAN. The identified contributor (sFlt-1) was further confirmed in a replication cohort, which included 109 IgAN patients and 30 healthy volunteers. Correlations of sFlt-1 with hypertension, proteinuria, Oxford-E score and plasma vWF were further evaluated in the combined 205 patients with IgAN. RESULTS:VEGF/sFlt-1 levels were significantly lower in IgAN patients than healthy volunteers (0.33±0.27 vs. 0.43±0.22, p = 0.02) in the discovery cohort. Within the ratio, plasma sFlt-1 levels were significantly elevated (101.18±25.19 vs. 79.73±18.85 pg/ml, p<0.001), but plasma VEGF levels showed no significant differences. Elevated sFlt-1 levels in the replication cohort were confirmed in IgAN patients (93.40±39.78 vs. 71.92±15.78 pg/ml, p<0.001). Plasma sFlt-1 levels in IgAN patients correlated with proteinuria (severe (>3.5 g/d) vs. moderate (1-3.5 g/d) vs. mild (<1 g/d) proteinuria: 115.95±39.09 vs. 99.89±28.55 vs. 83.24±33.92 pg/ml; severe vs. mild: p<0.001, moderate vs. mild p = 0.001, severe vs. moderate: p = 0.014), hypertension (with vs. without hypertension: 107.87±31.94 vs. 87.32±32.76 pg/ml, p = 0.015) and vWF levels (r = 0.161, p = 0.021). CONCLUSIONS:The present study found elevated sFlt-1 in IgAN patients and further identified its correlation with proteinuria, hypertension and vWF levels. These results suggested that elevated sFlt-1 contributes to endothelial injury in IgAN.

sFlt-1: A Double Regulator in Angiogenesis-related Diseases

Progress in Soluble Vascular Endothelial Growth Factor Receptor-1 and Preeclampsia

Potential role of soluble VEGFR-1 in antiangiogenesis therapy for cancer

Circulating Soluble Fms-like Tyrosine Kinase in Renal Diseases Other than Preeclampsia

Bioinformatics Analyses of the Role of Vascular Endothelial Growth Factor in Patients with Non-Small Cell Lung Cancer.

Vascular Endothelial Growth Factor and Atherosclerosis

VEGF Levels in Plasma in Relation to Metabolic Control, Inflammation, and Microvascular Complications in Type-2 Diabetes A Cohort Study

Positive and Negative Regulation of Angiogenesis by Soluble Vascular Endothelial Growth Factor Receptor-1

Soluble FLT-1 in angiogenesis: pathophysiological roles and therapeutic implications

FLI-1-driven regulation of endothelial cells in human diseases

Expression and clinical study of vascular endothelial growth factor and its receptors FLT-1, FLK-1/KDR in non-small cell lung cancer

Soluble Fms-Like Tyrosine Kinase 1 and Soluble Endoglin Are Elevated Circulating Anti-Angiogenic Factors in Pre-Eclampsia.

Soluble fms-like tyrosine kinase 1 and soluble endoglin are elevated circulating anti-angiogenic factors in pre-eclampsia

Elevated Soluble Vegf Receptor Sflt-1 Correlates with Endothelial Injury in Iga Nephropathy

Regulation of VEGF-A expression and VEGF-A-targeted therapy in malignant tumors

Vascular Endothelial Growth Factor-Dependent Spatiotemporal Dual Roles of Placental Growth Factor in Modulation of Angiogenesis and Tumor Growth

SFlt-1 elevates blood pressure by augmenting endothelin-1-mediated vasoconstriction in mice

Ang-1 and VEGF: central regulators of angiogenesis

Role of Angptl4 in vascular permeability and inflammation

Biology and therapeutic targeting of vascular endothelial growth factor A

The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions